Acciones Immunoprecise Antibodies Ltd Other OTC
Acciones
CA87588T1030
Farmacéuticos
Ventas 2024 * | 24,59 M 17,96 M 16,79 M | Ventas 2025 * | 29,82 M 21,78 M 20,36 M | Capitalización | 36,38 M 26,57 M 24,83 M |
---|---|---|---|---|---|
Resultado Neto 2024 * | -12 M -8,77 M -8,19 M | Resultado Neto 2025 * | -9 M -6,57 M -6,14 M | VE / Ventas 2024 * | 1,48 x |
Posición de caja neta 2024 * | - 0 0 | Posición de caja neta 2025 * | - 0 0 | VE / Ventas 2025 * | 1,22 x |
P/E ratio 2024 * |
-2,88
x | P/E ratio 2025 * |
-3,9
x | Empleados | - |
Rendimiento 2024 * |
-
| Rendimiento 2025 * |
-
| Flotante | 86,41 % |
Último transcript sobre Immunoprecise Antibodies Ltd
Directores | Puesto | Edad | Desde |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29/09/23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/21 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05/09/23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/18 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+2,99 % | 95,18 mil M | |
-4,34 % | 37,55 mil M | |
-10,41 % | 33,75 mil M | |
+75,79 % | 28,2 mil M | |
-14,61 % | 15,63 mil M | |
-3,46 % | 13,63 mil M | |
-12,31 % | 11,5 mil M | |
+184,77 % | 10,81 mil M | |
-54,13 % | 9233,36 M |